论文部分内容阅读
同种异体骨髓移植(BMT)已从实验阶段发展到对各种疾病的临床应用阶段,而且在过去二十年间应用逐渐增加。70年代,BMT仅应用于恶性疾病的晚期,其长期生存率甚低。80年代,恶性疾病非晚期进行BMT的病例日益增多,并已成为一些非恶性血液病的选择性治疗。同种异体BMT一般应用于希望有长期生存的年轻患者(年龄小于40岁),因而长期生存率逐渐增加。这些变化提示,在90年代,BMT的晚期并发症可能会成
Allogeneic bone marrow transplantation (BMT) has progressed from the experimental stage to the clinical application stage for various diseases and has been gradually increasing over the past two decades. In the 1970s, BMT was only applied to the advanced stage of malignant disease, its long-term survival rate is very low. In the 1980s, there was a growing number of cases of non-malignant disease that progressed to BMT non-later and has become a selective treatment for some non-hematologic malignancies. Allogeneic BMT is generally used in young patients (less than 40 years of age) who wish to have long-term survival, thus increasing long-term survival. These changes suggest that in the 90s, advanced complications of BMT may become